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background: BMS-962476 is an anti-human proprotein convertase subtilisin/kexin type 9 (PCSK9) Adnectin-based protein therapeutic formatted 
with 40 kDa branched polyethylene glycol being developed to prevent PCSK9-LDL receptor binding and reduce LDL cholesterol (LDL-C). We report 
safety, tolerability and efficacy of single ascending subcutaneous (SC) or intravenous (IV) doses of BMS-962476 in healthy subjects on diet or statins 
and LDL-C >130 or >100 mg/dL respectively (NCT01587365).
methods: At each dose 8 subjects were randomized 3:1 to a single SC or IV dose of BMS-962476 or placebo (PBO). Treatment began in diet only 
subjects with 0.01 mg/kg SC and based on tolerability escalated sequentially to 0.03, 0.1 and 0.3 mg/kg SC, followed by 0.3 and 1.0 mg/kg IV. 
Subjects on statins received 0.1 and 0.3 mg/kg SC doses. Free PCSK9 and LDL-C were measured but remained blinded. Subjects were confined for 
5 days post-dose and then followed as outpatients.
results: Of 64 randomized subjects 60 completed the 43 day study. There were 2 serious adverse events (SAE) considered unrelated to study-drug, 
none resulted in study discontinuation. BMS-962476 was well tolerated and AEs were similar to PBO. Maximal dose related reductions of LDL-C up 
to 48% occurred between day 4 and 14 (Table). Doses >0.3 mg/kg reduced free PCSK9 >90%.
conclusion: BMS-962476, a novel and effective anti-PCSK9 therapeutic agent, rapidly reduces free PCSK9 and LDL-C, and in this first in human 
study was well tolerated and had no notable safety signals.
 
